A select group of highly renowned scientists - among them four Nobel Prize Winners - have been asked to summarize significant developments of their ownrecent research in the life sciences at a workshop organized on the occasionof the opening of the new Paul-Ehrlich-Institut in Langen near Frankfurt/ Main. They do this in a comparative fashion evaluating similar achievements in adjacent fields. Their intellectual state-of-the-art analysis and fascinating outlook on future perspectives provides exciting and stimulating reading. The authors address areas in virology, immunology, oncology and evolution. Intelligent design of vaccines and other immunologial drugs, virus evolution and viruses as nature's engineers, pathology of chronic autoimmune and central nervous system diseases and the biology of mammary cancer belong to the topics discussed. A book easy to read for scientists, doctors and students interested in rapidly developing fields in the life sciences.

On February 26, 2020, the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine hosted a 1-day public workshop in Washington, DC, to examine current and emerging bioethical issues that might arise in the context of biomedical research and to consider research topics in bioethics that could benefit from further attention. The scope of bioethical issues in research is broad, but this workshop focused on issues related to the development and use of digital technologies, artificial intelligence, and machine learning in research and clinical practice; issues emerging as nontraditional approaches to health research become more widespread; the role of bioethics in addressing racial and structural inequalities in health; and enhancing the capacity and diversity of the bioethics workforce. This publication summarizes the presentations and discussions from the workshop.

This report is the twelfth assessment of the National Institutes of Health National Research Service Awards program. The research training needs of the country in basic biomedical, clinical, and behavioral and social sciences are considered. Also included are the training needs of oral health, nursing, and health services research. The report has been broadly constructed to take into account the rapidly evolving national and international health care needs. The past and present are analyzed, and predictions with regard to future needs are presented.

The nature of biomedical research has been evolving in recent years. Technological advances that make it easier to study the vast complexity of biological systems have led to the initiation of projects with a larger scale and scope. In many cases, these large-scale analyses may be the most efficient and effective way to extract functional information from complex biological systems. Large-Scale Biomedical Science: Exploring Strategies for Research looks at the role of these new large-scale projects in the biomedical sciences. Though written by the National Academies' Cancer Policy Board, this book addresses implications of large-scale science extending far beyond cancer research. It also identifies obstacles to the implementation of these projects, and makes recommendations to improve the process. The ultimate goal of biomedical research is to advance knowledge and provide useful innovations to society. Determining the best and most efficient method for accomplishing that goal, however, is a continuing and evolving challenge. The recommendations presented in Large-Scale Biomedical Science are intended to facilitate a more open, inclusive, and accountable approach to large-scale biomedical research, which in turn will maximize progress in understanding and controlling human disease.

This book gathers multidisciplinary articles that present advances of our understanding of diseases and the effective treatment of patients. The authors share recent clinical and experimental research findings, highlighting poorly understood areas with uncertain treatment outcomes, such as giant-cell bone tumors and their propensity to metastasize to the lungs; subterranean rehabilitation in pulmonary disorders; male reproductive hormone regulation during physical exercise in hyperbaric, hyperoxic environments, like underwater diving; and amelioration of cognitive decline owing to increased cerebral blood transit time after internal carotid artery stenting. Other topics include new concepts and innovations in the treatment of diabetes in pregnancy, and leg ulcers in chronic venous insufficiency, as well as molecular research on the toxic effects of oxidative stress, impaired cell autophagy, and experimental conditions resembling air pollution. Featuring the latest interdisciplinary advances in biomedicine, this book is a valuable resource for medical professionals, both academics and practitioners, and all allied health-care workers.

In the realm of health care, privacy protections are needed to preserve patients' dignity and prevent possible harms. Ten years ago, to address these concerns as well as set guidelines for ethical health research, Congress called for a set of federal standards now known as the HIPAA Privacy Rule. In its 2009 report, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research, the Institute of Medicine's Committee on Health Research and the Privacy of Health Information concludes that the HIPAA Privacy Rule does not protect privacy as well as it should, and that it impedes important health research.

Today we witness an eventful time in which the powerful new forces of genomics, information technology and economics are rapidly changing the science and art of medicine. This will require more specialization than ever before. However, there is also an increasing demand for an integrated approach, which is provided by the discipline of Clinical Pharmacology (CP). CP pursues a scientific goal by studying drug action in patients and volunteers, a clinical goal by administering appropriate drug therapy and a regulatory goal by assessing the risk/benefit ratio of drug candidates in drug development and reimbursement. This introduction to current topics of CP covers traditional topics of clinical drug research and trial methodology but also provides insight in current topics like genomics, imaging technology and issues in drug reimbursement. A number of concrete case studies in clinical drug research and development help to give a better understanding of the general principles of CP.

Drawing on the work of the Roundtable on Evidence-Based Medicine, the 2007 IOM Annual Meeting assessed some of the rapidly occurring changes in health care related to new diagnostic and treatment tools, emerging genetic insights, the developments in information technology, and healthcare costs, and discussed the need for a stronger focus on evidence to ensure that the promise of scientific discovery and technological innovation is efficiently captured to provide the right care for the right patient at the right time. As new discoveries continue to expand the universe of medical interventions, treatments, and methods of care, the need for a more systematic approach to evidence development and application becomes increasingly critical. Without better information about the effectiveness of different treatment options, the resulting uncertainty can lead to the delivery of services that may be unnecessary, unproven, or even harmful. Improving the evidence-base for medicine holds great potential to increase the quality and efficiency of medical care. The Annual Meeting, held on October 8, 2007, brought together many of the nation's leading authorities on various aspects of the issues - both challenges and opportunities - to present their perspectives and engage in discussion with the IOM membership.

This edited volume discusses the application of very diverse human organotypic models in major areas of biomedical research. The authors lay a main focus on infectious diseases, cancer, allergies, as well as drug/vaccine discovery and toxicology studies. Representing a valid alternative to laboratory animals, these models are relevant for most areas of translational research. As the contemporary research shows, many human tissues can today be cultivated in vitro and used for several research objectives. This book provides an unprecedented overview of recent developments in an exciting field of research methodology. It is a reference guide for scientists in both academia and industry. Readers can update their knowledge and get hands-on recommendations on how to set up an organotypic model in their lab. Chapters 'Progress on Reconstructed Human Skin Models for Allergy Research and Identifying Contact Sensitizers' and 'Human Organotypic Models for Anti-infective Research' of this book are available open access under a CC BY 4.0 license at link.springer.com.

The National Institutes of Health (NIH) is the primary agency of the United States government responsible for biomedical and public health research. Founded in the late 1870s, NIH has produced extraordinary advances in the treatment of common and rare diseases and leads the world in biomedical research. It is a critical national resource that plays an important role in supporting national security. The 310-acre Bethesda campus supports some 20,000 employees and contractors, and it contains more than 12 million square feet of facilities divided amongst nearly 100 buildings, including the largest dedicated research hospital in the world. The Bethesda campus supports some of the most sophisticated and groundbreaking biomedical research in the world. However, while some new state-of-the-art buildings have been constructed in recent years, essential maintenance for many facilities and the campus overall has been consistently deferred for many years. The deteriorating condition of NIH's built environment is now putting its ability to fulfill its mission at substantial risk. Managing the NIH Bethesda Campus's Capital Assets for Success in a Highly Competitive Global Biomedical Research Environment identifies the facilities in greatest need of repair on the Bethesda campus and evaluates cost estimates to determine what investment is needed for the NIH to successfully accomplish its mission going forward.